Company intelligence / Profile preview
Alaunos Therapeutics
Houston, Texas, United States of Americaalaunos.com ↗
- Ownership
- Public · TCRT
- Employees
- ~35
- Development stage
- Phase 1
01
Overview
The company has demonstrated first-in-human response for non-viral TCR-T therapy targeting high frequency TP53 and KRAS driver mutations across multiple solid tumor indications. Treatment was well tolerated with a manageable safety profile and persistence of TCR-T cells in peripheral blood observed in all three treated patients at last follow-up as of May 2023[5].
- Therapeutic areas
- Oncology
- Modalities
- T-cell receptor (TCR) cell therapiesGene-edited T cell therapies
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
03
Partnerships
MD Anderson Cancer Center
04
Financials
- Market cap
- $6.3M
- Total revenue
- $5K
- Enterprise value
- $6.2M
Beyond the preview
Go deeper on Alaunos Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alaunos Therapeutics.